Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

By Olivares J. M.   Peuskens J.   Pecenak J.   Resseler S.   Jacobs A.   Akhras K. S.  

Current Medical Research and Opinion, Vol. 25, Iss. 9, 2009-09 ,pp. : 2197-2206

Informa Healthcare

Access to resources Recommend Favorite

Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report

By  

Current Drug Safety, Vol. 7, Iss. 1, 2012-02 ,pp. : 21-23

Bentham Science Publishers

Access to resources Recommend Favorite

Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data

By Frey Simon   Linder Roland   Juckel Georg   Stargardt Tom  

The European Journal of Health Economics, Vol. 15, Iss. 2, 2014-03 ,pp. : 133-142

Springer Publishing Company

Access to resources Recommend Favorite

Risperidone long‐acting injection and 1‐year rehospitalization rate of schizophrenia patients: A retrospective cohort study

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 69, Iss. 8, 2015-08 ,pp. : 497-503

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 2-9

Bentham Science Publishers

Access to resources Recommend Favorite